Pashtoon Kasi, MD
Medical Oncology · Irvine, CANPI 1215167648
Payments from drug & device makers
Across 202 payments — averaging $15,498 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$852K
- Novartis$778K
- Tersera Therapeutics LLC$442K
- Amgen$218K
- Clovis Oncology, Inc.$217K
- AstraZeneca$203K
- plus $420K from 22 others
Across 4 payments — averaging $1540.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$6K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 19 | $852,459 |
| Novartis | 6 | $778,246 |
| Tersera Therapeutics LLC | 1 | $441,996 |
| Amgen | 8 | $217,854 |
| Clovis Oncology, Inc. | 21 | $216,854 |
| AstraZeneca | 19 | $203,477 |
| Seagen Inc. | 24 | $150,389 |
| Array Biopharma Inc | 4 | $75,225 |
| E.r. Squibb & Sons, L.L.C. | 4 | $61,855 |
| Biontech SE | 6 | $51,546 |
| Incyte Corporation | 61 | $35,835 |
| Regeneron | 5 | $13,583 |
| Lilly USA, LLC | 1 | $6,300 |
| Eisai Inc. | 3 | $4,684 |
| Bayer | 3 | $4,313 |
| Illumina, Inc. | 1 | $3,120 |
| Boston Scientific | 1 | $2,959 |
| Daiichi Sankyo Inc. | 2 | $2,775 |
| Beigene USA, Inc. | 2 | $2,357 |
| Servier Pharmaceuticals LLC | 1 | $2,240 |
| Taiho Oncology, Inc. | 1 | $1,980 |
| Menarini Silicon Biosystems, Inc. | 2 | $209 |
| Genentech USA, Inc. | 1 | $127 |
| GSK | 1 | $67 |
| Ipsen Biopharmaceuticals, Inc | 2 | $51 |
| Tempus AI, Inc | 1 | $27 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $16 |
How this compares
$3,130,566 in reported general payments places this provider in the 90th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Irvine
- Sarmad SadeghiLos Angeles$26.1M
- Marwan FakihDuarte$24.2M
- Sumanta PalDuarte$15.9M
- Farshid DayyaniOrange$13.4M
- Daneng LiDuarte$12.4M
- Heinz-Josef LenzLos Angeles$11.6M
- Kevin KimSan Francisco$10.8M
- Anthony El-KhoueiryLos Angeles$10.5M
- Amy ChienSan Francisco$10.5M
- Sandhya SrinivasStanford$10.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.